These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33012706)

  • 1. The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4.
    Turner MJ; Dauletbaev N; Lands LC; Hanrahan JW
    J Pharmacol Exp Ther; 2020 Dec; 375(3):414-429. PubMed ID: 33012706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants.
    Turner MJ; Luo Y; Thomas DY; Hanrahan JW
    Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L908-L920. PubMed ID: 32159371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia.
    Turner MJ; Matthes E; Billet A; Ferguson AJ; Thomas DY; Randell SH; Ostrowski LE; Abbott-Banner K; Hanrahan JW
    Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(1):L59-70. PubMed ID: 26545902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials.
    Cazzola M; Page C; Calzetta L; Singh D; Rogliani P; Matera MG
    Immunotherapy; 2023 Dec; 15(18):1511-1519. PubMed ID: 37779474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.
    Cazzola M; Calzetta L; Rogliani P; Matera MG
    Expert Opin Investig Drugs; 2019 Oct; 28(10):827-833. PubMed ID: 31474120
    [No Abstract]   [Full Text] [Related]  

  • 6. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
    BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
    Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits TNF-alpha-induced GM-CSF production by a human bronchial epithelial cell line via inhibition of PDE4.
    Sasaki K; Manabe H
    Inflamm Res; 2004 Jan; 53(1):31-7. PubMed ID: 15021978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
    Cazzola M; Page C; Calzetta L; Matera MG
    Pharm Pat Anal; 2018 Nov; 7(6):249-257. PubMed ID: 30657422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells.
    Patel BS; Prabhala P; Oliver BG; Ammit AJ
    Am J Respir Cell Mol Biol; 2015 May; 52(5):634-40. PubMed ID: 25296132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis.
    Stolarz AJ; Farris RA; Wiley CA; O'Brien CE; Price ET
    Clin Transl Sci; 2015 Dec; 8(6):696-701. PubMed ID: 26258991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors.
    Dent G; White SR; Tenor H; Bodtke K; Schudt C; Leff AR; Magnussen H; Rabe KF
    Pulm Pharmacol Ther; 1998 Feb; 11(1):47-56. PubMed ID: 9802963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity.
    Koyama S; Sato E; Masubuchi T; Takamizawa A; Kubo K; Nagai S; Isumi T
    Eur Respir J; 1999 Oct; 14(4):767-75. PubMed ID: 10573218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone.
    Calzetta L; Page CP; Spina D; Cazzola M; Rogliani P; Facciolo F; Matera MG
    J Pharmacol Exp Ther; 2013 Sep; 346(3):414-23. PubMed ID: 23766543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation.
    Hallows KR; Fitch AC; Richardson CA; Reynolds PR; Clancy JP; Dagher PC; Witters LA; Kolls JK; Pilewski JM
    J Biol Chem; 2006 Feb; 281(7):4231-41. PubMed ID: 16361706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
    Tannheimer SL; Wright CD; Salmon M
    Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
    Lambert JA; Raju SV; Tang LP; McNicholas CM; Li Y; Courville CA; Farris RF; Coricor GE; Smoot LH; Mazur MM; Dransfield MT; Bolger GB; Rowe SM
    Am J Respir Cell Mol Biol; 2014 Mar; 50(3):549-58. PubMed ID: 24106801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines.
    Kube D; Sontich U; Fletcher D; Davis PB
    Am J Physiol Lung Cell Mol Physiol; 2001 Mar; 280(3):L493-502. PubMed ID: 11159033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roflumilast partially reverses smoke-induced mucociliary dysfunction.
    Schmid A; Baumlin N; Ivonnet P; Dennis JS; Campos M; Krick S; Salathe M
    Respir Res; 2015 Oct; 16():135. PubMed ID: 26521141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined anti-inflammatory effects of β2-adrenergic agonists and PDE4 inhibitors on astrocytes by upregulation of intracellular cAMP.
    Christiansen SH; Selige J; Dunkern T; Rassov A; Leist M
    Neurochem Int; 2011 Nov; 59(6):837-46. PubMed ID: 21871511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ensifentrine: First Approval.
    Keam SJ
    Drugs; 2024 Sep; 84(9):1157-1163. PubMed ID: 39196510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.